'Moving From Spot Business To Structured Customer Programmes': Morepen Labs CMD On Rs 825 Crore CDMO Deal

Morepen Laboratories, under the leadership of its CMD, has announced a significant transition from traditional spot business to structured customer programs, highlighted by a substantial contract manufacturing deal worth Rs 825 crore. This move reflects the company's strategy to enhance its operational framework and establish long-lasting partnerships within the pharmaceutical sector. The contract is expected to initiate supplies within the next four to five months, marking a crucial step in Morepen's growth trajectory. This deal not only strengthens Morepen's position in the competitive market but also aligns with the increasing demand for contract development and manufacturing organization (CDMO) services in India. The CMD emphasized the importance of this strategic shift, aiming to provide more tailored solutions to clients and improve overall service delivery in the industry. With this development, Morepen Labs is poised to leverage its expertise and resources to meet the evolving needs of its customers, ensuring both efficiency and quality in its product offerings.